As the election draws near, the diverging positions of Vice President Kamala Harris and former President Donald Trump on pharmaceutical policies are becoming more apparent.
Harris is advocating for expanded Medicare provisions, including the authority to negotiate drug prices. She aims to extend the $35 monthly cap on insulin and the $2,000 annual out-of-pocket maximum for Medicare recipients to all Americans. Harris also wants to accelerate drug price negotiations and increase coverage of in-home healthcare.
On the other hand, Trump has shifted his stance and aligned more closely with industry lobbyists who oppose key elements of the Inflation Reduction Act (IRA). He has abandoned his previous support for a "most-favored nations" policy and distanced himself from policies that could be seen as price controls.
Financially, Harris has received significant support from the pharmaceutical sector, while Trump has received less.
The candidates' approaches to pharmaceutical policy will have a significant impact on the future of drug pricing and the regulatory landscape in the United States.